The cell cycle regulator CDC25A is a target for JAK2V617F oncogene

Upregulation of the CDC25A phosphatase downstream of the NPM/ALK oncogene participates in anaplastic large cell lymphoma enhanced proliferation

(2011) Anne Fernandez-Vidal et al.   CELL CYCLE

Myeloproliferative neoplasm induced by constitutive expression of JAK2V617F in knock-in mice

(2010) C. Marty et al.   BLOOD

Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease

(2010) H. Akada et al.   BLOOD

Recent developments on JAK2 inhibitors: a patent review

(2010) Róbert Kiss et al.   EXPERT OPINION ON THERAPEUTIC PATENTS

Inhibitors of Cdc25 phosphatases as anticancer agents: a patent review

(2010) Antonio Lavecchia et al.   EXPERT OPINION ON THERAPEUTIC PATENTS

eIF2α Phosphorylation Tips the Balance to Apoptosis during Osmotic Stress

(2010) Elena Bevilacqua et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Ubiquitin hydrolase Dub3 promotes oncogenic transformation by stabilizing Cdc25A

(2010) Yaron Pereg et al.   NATURE CELL BIOLOGY

p27 deregulation by Skp2 overexpression induced by the JAK2V617 mutation

(2009) A. Furuhata et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

GSK-3β Targets Cdc25A for Ubiquitin-Mediated Proteolysis, and GSK-3β Inactivation Correlates with Cdc25A Overproduction in Human Cancers

(2008) Tiebang Kang et al.   CANCER CELL

Multimodal Control of Cdc25A by Nitrosative Stress

(2008) R. J. Tomko et al.   CANCER RESEARCH

IRC-083864, a novel bis quinone inhibitor of CDC25 phosphatases active against human cancer cells

(2008) Marie-Christine Brezak et al.   INTERNATIONAL JOURNAL OF CANCER

New mutations of MPL in primitive myelofibrosis: only the MPL W515 mutations promote a G1/S-phase transition

(2008) R Chaligné et al.   LEUKEMIA